Skip to main content
Clinical Trials/JPRN-UMIN000007842
JPRN-UMIN000007842
Completed
Phase 1

A phase I/II study of concurrent chemoradiotherapy (RT-DeVIC) for newly-diagnosed, localized nasal NK/T-cell lymphoma (JCOG0211-DI) - A phase I/II study of concurrent chemoradiotherapy (RT-DeVIC) for newly-diagnosed, localized nasal NK/T-cell lymphoma (JCOG0211-DI)

Japan Clinical Oncology Group (JCOG)0 sites33 target enrollmentApril 27, 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
extranodal NK/T-cell lymphoma, nasal type
Sponsor
Japan Clinical Oncology Group (JCOG)
Enrollment
33
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2012
End Date
December 28, 2011
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Clinical Oncology Group (JCOG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Clinical symptoms of Central nervous system involvement 2\) Uncontrollable diabetes mellitus 3\) Uncontrollable hypertension 4\) History of myocardial infarction or angina, and/or cardiomyopathy, and/or arrhythmia treated with antiarrhythmic 5\) Positive test for HBs antigen 6\) Positive test for HIV antibody 7\) Interstitial pneumonia, pulmonary fibrosis or severe pulmonary emphysema 8\) Severe infection 9\) Liver cirrhosis 10\) Other active malignancies 11\) Pregnant, possible pregnant, or breastfeeding woman 12\) Use of major tranquilizer, antidepressant, or antimanic 13\) Severe psychosis 14\) Patients or their families, and/or attending physicians hoping hematopoietic stem cell transplantation after obtained responses by RT\-DeVIC

Outcomes

Primary Outcomes

Not specified

Similar Trials